Pharmanutra SpA
MIL:PHN

Watchlist Manager
Pharmanutra SpA Logo
Pharmanutra SpA
MIL:PHN
Watchlist
Price: 53.8 EUR 0.19% Market Closed
Market Cap: 516.9m EUR
Have any thoughts about
Pharmanutra SpA?
Write Note

Operating Margin
Pharmanutra SpA

21.9%
Current
26%
Average
5.5%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
21.9%
=
Operating Profit
33.3m
/
Revenue
152.2m

Operating Margin Across Competitors

Country IT
Market Cap 516.9m EUR
Operating Margin
22%
Country FR
Market Cap 176B EUR
Operating Margin
19%
Country UK
Market Cap 117.3B GBP
Operating Margin
18%
Country IN
Market Cap 5.7T INR
Operating Margin
22%
Country UK
Market Cap 34.7B GBP
Operating Margin
19%
Country DE
Market Cap 27.7B EUR
Operating Margin
11%
Country US
Market Cap 25.1B USD
Operating Margin
10%
Country JP
Market Cap 2.9T JPY
Operating Margin
7%
Country IN
Market Cap 1.2T INR
Operating Margin
21%
Country IN
Market Cap 909.1B INR
Operating Margin
15%
Country US
Market Cap 10.2B USD
Operating Margin
19%
No Stocks Found

Pharmanutra SpA
Glance View

Market Cap
516.9m EUR
Industry
Consumer products

Pharmanutra SpA develops nutraceutical products and medical devices. The company is headquartered in Pisa, Pisa. The company went IPO on 2017-07-18. The firm develops nutraceutical products and medical devices. The company focuses on studying and producing formulations that are backed up in scientific research. The company is able to cover all stages of the development of a product, from its design, formulation and registration to its marketing, distribution and training of its commercial representatives. The firm offers Gestalys DHA, a nutritional supplement; Cetilar, a massage coadiuvant, improves and brings relief to joints affected by osteoarthritis; Cetilar patch, a transdermic patch containing a concentrated formulation of cetylated fatty acids (CFA) esters; SiderAL Forte; CardioSiderAL; SiderAL Folico; SiderAL; Bonecal and Novomega, among others.

PHN Intrinsic Value
43.41 EUR
Overvaluation 19%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
21.9%
=
Operating Profit
33.3m
/
Revenue
152.2m
What is the Operating Margin of Pharmanutra SpA?

Based on Pharmanutra SpA's most recent financial statements, the company has Operating Margin of 21.9%.